MedTrace Logo

Comparing the Efficacy and Safety of Different Postoperative Adjuvant Regimens in Patients With Resectable Adenocarcinoma of the Esophagogastric Junction Who Underwent Radical Surgery After Neoadjuvant Chemotherapy Combined With Immunotherapy and Achieved pCR in Postoperative Pathology

NCT07161453 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2025-09-08

No results posted yet for this study

Summary

This study is to evaluate the efficacy and safety of different postoperative adjuvant regimens in patients with resectable adenocarcinoma of the esophagogastric junction who underwent radical surgery after neoadjuvant chemotherapy combined with immunotherapy and achieved pCR in postoperative pathology

Conditions

  • Gastric / Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG

SOX plus PD-1 inhibitor

SOX or XELOX plus PD-1 inhibitor

DRUG

PD-1 / PD-L1 monoclonal antibody

PD-1/PD-L1 monoclonal antibody

DRUG

SOX Chemotherapy

SOX or XELOX

DRUG

Tegafur-Ugotex or Capecitabine

Tegafur-Ugotex or Capecitabine

Sponsors & Collaborators

  • Liaoning Cancer Hospital & Institute

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-30
Primary Completion
2027-09-30
Completion
2027-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07161453 on ClinicalTrials.gov